Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Asthma exacerbations are often triggered by factors such as respiratory infections, allergens, exercise, and airway irritants, significantly affecting patients' respiratory symptoms and quality of life. Effective management of triggers is crucial in severe asthma care. Tezepelumab, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, can effectively reduce severe asthma exacerbations and symptoms burden. However, its impact on patients' perception of trigger-related symptoms remains underexplored.

Methods: We conducted an observational, multicenter study involving 30 severe asthma patients starting tezepelumab 210 mg every 4 wk. Asthma triggers were assessed with the Asthma Triggers Inventory (ATI), while respiratory symptoms and HRQoL were evaluated using the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), and Asthma Quality of Life Questionnaire (AQLQ). Data were collected at baseline (T0) and after 3 months of treatment (T3).

Results: At T3, patients demonstrated a significant reduction in the impact of asthma triggers as well as improvements in the perception of triggers effects on HRQoL. Specific improvements were observed in the "air pollution/irritants" and "infection" domains of the ATI. Correlation analysis revealed a significant association between ATI and AQLQ changes over time.

Conclusion: Tezepelumab positively impacts patients' perception of asthma triggers and their HRQoL, supporting its role in managing triggers hypersensitivity as a treatable trait in severe asthma. Further research is warranted to investigate underlying mechanisms and long-term effects.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02770903.2025.2495725DOI Listing

Publication Analysis

Top Keywords

asthma triggers
20
severe asthma
16
asthma
13
triggers
8
asthma exacerbations
8
respiratory symptoms
8
quality life
8
patients' perception
8
asthma control
8
impact tezepelumab
4

Similar Publications

Formoterol, a Clinically Approved Drug, Inhibits Ferroptosis by Suppressing Lipid Peroxidation and Attenuates APAP-Induced Acute Liver Injury.

Chem Biol Interact

September 2025

College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, Jinan 250014, China. Electronic address:

Ferroptosis is an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation and implicated in various human diseases. Despite intensive research, clinically applicable ferroptosis inhibitors remain unavailable. In this study, we identify formoterol, a β-adrenergic agonist widely used to treat asthma and COPD, as a potent and selective ferroptosis inhibitor through scaffold-based screening of FDA-approved drugs.

View Article and Find Full Text PDF

Cofactors are external factors that can lower the threshold dose of an allergen and amplify the severity of allergic reactions, turning mild or moderate responses into severe anaphylaxis. These include exercise, nonsteroidal anti-inflammatory drugs (NSAIDs), alcohol, menstruation, and infections. Initially described in relation to food allergens and physical activity or NSAIDs, these reactions have been labeled under various terms, such as food-dependent exercise-induced anaphylaxis (FDEIA), wheat-dependent exercise-induced anaphylaxis (WDEIA), and food-dependent NSAID-induced anaphylaxis (FDNIA).

View Article and Find Full Text PDF

eyelash mites are increasingly associated with eye and skin inflammation in humans, and cause demodectic mange in mammals. Informal accounts of symptom improvement and reduced need for anti-allergy medicines, when reproduction is prevented, indicate a further role linking to rhinitis, asthma and dermatitis. Their mobility, allergenic debris and consequential immunological impact may also explain progression of allergies in the .

View Article and Find Full Text PDF

Risk of Infective Endocarditis Following Invasive Dental Procedures in Patients With Congenital Heart Disease.

Can J Cardiol

September 2025

School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan; Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan. Electronic address:

Background: Invasive dental procedures (IDPs) may trigger infective endocarditis (IE) in patients with congenital heart disease (CHD). However, data quantifying this risk remain limited. This study aimed to investigate the association between IDPs and the risk of IE in CHD.

View Article and Find Full Text PDF

HLA-A*02:01 Presents Penicillin-Modified Cysteinylated Peptides for T Cell Recognition.

Allergy

September 2025

Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.

Background: A subset of patients experience immune-mediated hypersensitivity reactions towards β-lactam antibiotics, with drug-specific T cells implicated as one of the causative factors. The principal mechanism is thought to involve chemical haptenation of self-peptides, resulting in novel peptide drug-adducts that may trigger T cell recognition. Understanding the interactions between the β-lactam drug, the T cell receptor (TCR) and the peptide/human leukocyte antigen (pHLA) complex is critical to gain further mechanistic insights into these hypersensitivity reactions.

View Article and Find Full Text PDF